|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Regulus Therapeutics, Inc. Reports Third Quarter 2012 Financial Results and Recent Highlights
11/20/2012 8:41:25 AM
LA JOLLA, Calif., Nov. 19, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the quarter ended September 30, 2012 and provided a summary of recent corporate highlights.
"The third quarter and subsequent period were the most successful to date for Regulus as measured by the achievement of significant financial and strategic goals," said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus. "Regulus is now focused on the execution of our research and development plans that include selection of clinical candidates in all of our microRNA therapeutic programs, which we believe will enable us to file at least two INDs by 2014."
|
|
|
|
|
|
|
|
|
|
|